AlloVir (ALVR) Stock Price, News & Analysis

Company Overview

AlloVir, Inc. is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.

AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings. ALVR105 is being evaluated for the treatment of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease, while ALVR106 and ALVR107 are targeted against BK virus and cytomegalovirus (CMV), respectively. A fourth candidate, ALVR108, is being developed as a multivirus therapy to target a combination of common viral pathogens. All programs are in various stages of clinical or preclinical development, reflecting the company’s commitment to advancing novel immunotherapies through regulatory milestones.

Headquartered in Boston, Massachusetts, AlloVir serves a global market of transplant centers and healthcare institutions. The company’s leadership team brings together expertise in cell therapy, immunology and clinical development, supporting collaborations with academic centers and strategic partners to accelerate product development. AlloVir is publicly traded on the NASDAQ under the ticker symbol ALVR.

Key Stats

• Today's Range: $5.20 to $5.62
• 50-Day Range: $5.30 to $10.97
• 52-Week Range: $7.96 to $24.15
• Volume: 109,556 shs
• Average Volume: 15,685 shs
• Market Capitalization: $26.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALVR Stock Analysis - Frequently Asked Questions

How have ALVR shares performed this year?

AlloVir's stock was trading at $8.44 at the start of the year. Since then, ALVR stock has decreased by 37.2% and is now trading at $5.30.

How were AlloVir's earnings last quarter?

AlloVir, Inc. (NASDAQ:ALVR) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.15) EPS for the quarter, topping the consensus estimate of ($2.30) by $1.15.

When did AlloVir's stock split?

Shares of AlloVir reverse split on the morning of Thursday, January 16th 2025.The 1-23 reverse split was announced on Wednesday, January 15th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did AlloVir IPO?

AlloVir (ALVR) raised $276 million in an initial public offering (IPO) on Thursday, July 30th 2020. The company issued 16,250,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

How do I buy shares of AlloVir?

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AlloVir own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AlloVir investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALVR
• CIK: 1754068
• Web: www.allovir.com
• Phone: 617-433-2605
• Fax: N/A
• Employees: 110
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($20.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$190.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.03%
• Return on Assets: -61.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 86.78
• Quick Ratio: 86.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $29.35 per share
• Price / Book: 0.18

Miscellaneous

• Outstanding Shares: 5,043,000
• Free Float: 3,425,000
• Market Cap: $26.73 million
• Optionable: No Data
• Beta: 0.63